EPIPEN JR 0.15 MG / 0.3 ML

What is EPIPEN JR?

EPIPEN JR 0.15 MG / 0.3 ML contains EPINEPHRINE : 0.15 MG / 0.3 ML. It is listed in the Health Canada Drug Product Database under DIN 00578657, held by MYLAN SPECIALTY LP, supplied as SOLUTION for INTRAMUSCULAR administration. Health Canada currently lists it as marketed, status dated 20-May-2026. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.

What is EPIPEN JR used for?

EpiPen (0.3 mg Epinephrine Injection, USP, 0.3 mg/0.3 mL) and EpiPen Jr (0.15 mg Epinephrine Injection, USP, 0.15 mg/0.3 mL) are indicated for the emergency treatment of severe allergic reactions (anaphylaxis) in patients who are determined to be at increased risk for anaphylaxis, including individuals with a history of anaphylactic reactions. Selection of the appropriate dosage strength is determined according to patient body weight. EpiPen and EpiPen Jr are intended for immediate self-administration for the emergency treatment of severe allergic reactions (Type I), including anaphylaxis associated with: foods (e.g., peanuts, tree nuts, shellfish, fish, milk, eggs, and wheat); stinging insects (e.g., Order Hymenoptera, including bees, wasps, hornets, yellow jackets, and fire ants) and biting insects (e.g., mosquitoes and black flies); medications; latex; idiopathic anaphylaxis; exercise-induced anaphylaxis; other allergens.

Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.

Product details and regulatory record

How is it administered?

EpiPen and EpiPen Jr are intended for intramuscular administration into the anterolateral thigh, not the buttock. It is designed to inject through clothing or directly through the skin. The effective dose is usually in the range 0.005-0.01 mg/kg bodyweight. Adults: The usual dose is 0.3 mg for intramuscular use. Children and adolescents over 30 kg weight: The usual dose is 0.3 mg for intramuscular use. Children between 15 kg and 30 kg in weight: The usual dose is 0.15 mg for intramuscular use. Children between 7.5 kg and < 15 kg in weight: The suitability of EpiPen Jr has to be judged individually. Children below 7.5 kg in weight: The use is not recommended unless in a life-threatening situation and under medical advice. It is recommended that epinephrine be given at the start of any reaction. In the absence of clinical improvement or if deterioration occurs after the initial treatment, a second injection with an additional EpiPen or EpiPen Jr auto-injector may be necessary. The repeated injection may be administered 5 – 15 minutes after the first injection. All individuals receiving emergency epinephrine must be immediately transported to hospital for evaluation and observation.

Included because it drives pack selection and wastage. Consult the monograph.

How is it stored and handled?

Store at 20°C to 25°C, excursions permitted to 15°C-30°C. Do not refrigerate or freeze. Protect from light. Keep out of reach and sight of children. Always keep EpiPen or EpiPen Jr in the carrier tube to protect it from damage; however, the carrier tube is not waterproof. Periodically check to make sure the medicine in the auto-injector is not brown in color. Discard and replace if it is discolored or contains a precipitate. Do not use after the expiry date. Replace and discard the auto-injector after expiry date.

How is it supplied?

EpiPen: Unidose 0.3 mg epinephrine auto-injector. Each auto-injector contains 2 mL epinephrine injection 1 mg/mL and is designed to deliver a single dose of 0.3 mg epinephrine in 0.3 mL. EpiPen Jr: Unidose 0.15 mg epinephrine auto-injector. Each auto-injector contains 2 mL epinephrine injection 0.5 mg/mL and is designed to deliver a single dose of 0.15 mg epinephrine in 0.3 mL. EpiPen and EpiPen Jr come in disposable, prefilled automatic injection devices. They are single-use injectable devices that deliver a fixed dose of epinephrine.

Contraindications

There are no absolute contraindications to the use of epinephrine in a life-threatening allergic situation.

Warnings and precautions

EpiPen and EpiPen Jr are for immediate administration as emergency supportive therapy only and not a substitute for immediate medical care. Patients should seek immediate medical or hospital care after administration. All patients prescribed EpiPen/EpiPen Jr should be thoroughly instructed on its use. Patients with a history of anaphylaxis are at risk for subsequent episodes and death, and should always carry injectable epinephrine. Biphasic anaphylaxis (recurrence of symptoms 1 to 48 hours later) is possible. In patients with a thick subcutaneous fat layer, there is a risk of epinephrine not reaching muscle tissue, leading to suboptimal effect. Antihistamines and asthma medications are not first-line treatments for anaphylaxis. Adverse reactions may occur in patients with hyperthyroidism, phaeochromocytoma, severe renal impairment, prostate adenoma, hypercalcaemia, hypokalaemia, elderly patients, and pregnant women. Epinephrine should ONLY be injected into the anterolateral aspect of the thigh. Do not inject intravenously, into the buttock (risk of Clostridial infections/gas gangrene), or into digits, hands, or feet (risk of blood flow loss). Hold the leg firmly during injection in young children to prevent lacerations, bent needles, and embedded needles. Serious skin and soft tissue infections, including necrotizing fasciitis and myonecrosis caused by Clostridia, have been reported at the injection site. Seek medical care for signs of infection. The presence of certain conditions (cardiac arrhythmias, coronary artery or organic heart disease, hypertension, diabetes, Parkinson's disease, narrow-angle glaucoma, asthma) is not a contraindication in acute, life-threatening situations, but caution is advised.

What can be used instead?

Other Canadian products sharing ATC code C01CA24 EPINEPHRINE. 7 of 29 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.